生物科技報告

過濾

Reset filter
2023/9/26 報告

Hemophilia - Global Clinical Trial Landscape

Hemophilia, a rare X-linked congenital bleeding disorder, is characterized by a deficiency of either factor VIII (FVIII) in hemophilia A or factor IX (FIX) in hemophilia B, also known as Christmas

下載
2023/9/22 報告

原發性膽汁性膽管炎：全球臨床試驗概況

原發性膽汁性膽管炎（PBC）是一種慢性肝臟疾病，特徵為對膽管的淋巴細胞T細胞介導性損傷，如果未治療可能導致膽汁性肝硬化和肝衰竭。此疾病主要影響女性，特別是在30幾歲和40幾歲，女性的發病率比較高。此疾病在全球各地的發病率和盛行率不同，亞太地區和歐洲的比率較高。南韓、希臘和加拿大在其各自地區的盛行率最高。

下載
2023/9/1 報告

鼻咽癌：全球臨床試驗概況

鼻咽癌是源於鼻咽上皮最常見的癌症，通常是未分化癌。此癌症主要發現於亞洲和非洲。非角化型鼻咽癌佔所有鼻咽癌案例大約 50%。在新式治療時代期間，全世界鼻咽癌 5 年存活率是 40-70%。2020 年，超過 130,000 個鼻咽癌病例對全球造成衝擊，使得鼻咽癌成為世界上第 23 常見癌症。男性比女性更可能發生鼻咽癌，男女比例為 2-3 比 1。

下載
2023/8/28 報告

膽囊癌：全球臨床試驗概況

惡性腫瘤細胞在膽囊黏膜層中增生並向外擴展，就會逐漸形成膽囊癌。最盛行的膽管癌佔全世界案例的 80%-95%，在胃腸道癌症排名第六。全球統計數據顯示女性比男性更容易罹患此疾病，2020 年記錄超過一百萬例新案例。值得注意的是，亞洲佔大多數案例和死亡人數，而歐美的案例相對較少。

下載
2023/6/28 報告

頭頸部癌症-全球臨床試驗概況-聚焦亞太地區。

2020 年，亞洲佔全球頭頸部癌症近 65% 的發病案例。 雖然印度和中國占大多數病例，但印度和澳洲的唇癌和口腔癌發病率最高。

下載
2023/6/26 報告

肝癌 – 全球臨床試驗概況 - 聚焦亞太地區

2020 年，亞洲佔全球肝癌發病率病例的 70% 以上，其中以中國占大多數。預計 2020 年至 2040 年間，每年全球疾病發病率將增加 55.0%。

下載
2023/5/26 報告

非何杰金氏淋巴瘤 – 全球臨床試驗概況 - 聚焦於亞太地區

2020 年，亞洲佔全球非何杰金氏淋巴瘤 40% 以上的發病率，其中又以中國佔最多數

下載
2023/5/24 報告

克隆氏症 (Crohn's Disease)-全球臨床試驗綜覽-聚焦亞太地區。

亞洲，特別是澳洲和紐西蘭，克隆氏症 (Crohn's Disease) 的發病率居冠，而東亞 自 2015 年以來，發病率和盛行率均呈現上升趨勢。

下載
2023/4/28 報告

卵巢癌 – 全球臨床試驗概況 - 聚焦亞太地區

2020 年，亞洲佔全球卵巢癌發病病例的一半以上，其中大部分的病例來自中國和印度。

下載
2023/4/27 報告

黑色素瘤 - 全球臨床試驗概況 - 聚焦亞太地區

亞洲在 2020 年產生了近 24,000 例黑色素瘤病例，以澳洲和紐西蘭的發病率佔世界首位。

下載
2023/4/6 報告

乳癌 - 全球臨床試驗概概況 - 以亞太地區為主。

亞洲約佔 2020 年全球乳癌病例的 45%，多數病例分布在中國大陸、印度和日本

下載
2023/4/5 報告

攝護腺癌 - 全球臨床試驗概況 - 以亞太地區為主

2020 年，亞洲在全世界攝護腺癌發病例中佔了四分之一以上，而中國和日本兩國在此地區共有超過 220,000 起新發病例。

下載
2023/3/3 報告

急性骨髓性白血病 (AML) - 全球臨床試驗概況 - 著重於亞太地區。

2020 年亞太地區約有 46,000 AML 病例，其中中國、印度和日本佔全球 40% 的病例。

下載
2023/2/20 報告

類風溼性關節炎 - 全球臨床試驗概況 - 著重於亞太地區

印度與中國的類風溼性關節炎盛行率最高，分別有 1 千萬及 5 百萬例，且觀察到東亞的年齡標準化發生率和盛行率增加速度最快。

下載
2023/1/19 報告

阿茲海默症 (AD) - 亞太地區 - 臨床試驗概況

阿茲海默症是失智症最常見的病因，並且截至 2030 年，亞太地區的病例預計將佔全球所有失智症病例的一半以上。

下載
2023/1/9 報告

Idiopathic Pulmonary Fibrosis - Asia Pacific – Clinical Trial Landscape

The global burden of IPF is expected to rise, due to the rapidly aging population of Asia Pacific region, with South Korea, in particular, having the highest incidence and prevalence rates of IPF.

下載
2022/12/16 報告

慢性阻塞性肺病 (COPD) - 亞太地區 - 臨床試驗概況

並排顯示文字：2019 年亞太地區 COPD 盛行率達 13.5%，超過全球平均值，其中最高盛行率出現在中國大陸。直到今日，此地區的疾病負擔和死亡率明顯高出西方國家，顯示這個趨勢仍在不斷攀升。

下載
2022/12/8 報告

花生過敏 – 亞太地區 – 臨床試驗前景

與西方類似，澳洲在亞太地區的花生過敏率最高，影響約 3% 的兒童。

下載
2022/11/25 報告

青光眼 – 亞太地區 – 臨床試驗前景

由於人口基數龐大且高齡化，亞洲佔估計全球青光眼病例的 60% 以上。

下載
2022/11/18 報告

Diabetic Retinopathy Asia Pacific – Clinical Trial Landscape

Asia-Pacific region accounts for 51% of all blindness cases and 56% of cases of visual impairment worldwide due to Diabetic Retinopathy

下載
2022/10/12 報告

陣發性夜間血紅素尿症 (Paroxysmal nocturnal hemoglobinuria，PNH) – 亞太地區 – 臨床試驗狀 況。

根據估計，西方地區國家每年每百萬人有 1- 2 起病例患有 PNH，而亞洲地區每年每百萬人約 10 起病例，其中又以中國和印度的 PNH 病例最多。

下載
2022/10/10 報告

C3G 腎絲球病變 (Glomerulopathy) – 亞太地 區 – 臨床試驗狀況

1990 年起至 2019 年間，亞洲地區腎絲球腎 炎 (Glomerulonephritis) 病症的年齡標準化發生率和 盛行率增加幅度遠勝西方地區，特別是南亞地區。

下載
2022/9/29 報告

膽管癌 (Cholangiocarcinoma) 亞太地區 – 臨床 試驗狀況

與世界各地相比，亞洲地區膽管癌盛行率顯著較 高，其中以中國、南韓、泰國與台灣的發生率最 高。 收購及整合長期經營的全方位服務 CRO 合作夥 伴之後，Novotech 現在能為全美國提供服務。

下載
2022/9/27 報告

亞太地區潰瘍性結腸炎 - 臨床試驗概況

過去 40 年來，亞洲的 UC 發病率和盛行率已快速增加， 尤其是在澳洲和日本

下載
2022/9/1 報告

亞太地區的非酒精性脂肪肝炎 (NASH) —臨床試驗現況

摘要——由於亞太地區老齡人口佔全球比例較高，並且相較於西方國家，亞太地區 NASH 盛行率較高 (~60%)，尤其是南亞國家，因此預計全球 NASH 負擔將會提高。

下載
2022/9/1 報告

亞太地區的困難梭狀芽孢桿菌感染症 (CDI) —臨床試驗現況

2019 年，亞洲地區困難梭狀芽孢桿菌感染症佔全球近 15% 的整體盛行率及近 10% 的死亡率。

下載
2022/8/22 報告

Diffuse large b-cell Lymphoma – Asia Pacific – Clinical trial landscape

Asia accounted for nearly 70% of the global incidence of DLBCL in 2020, with Mainland China, India, and Japan contributing to a third of all DLBCL cases worldwide.

下載
2022/8/2 報告

Brain/central nervous System (cns) tumors – Asia pacific – clinical Trial landscape

Asia accounted for more than 50% of the global incidence of brain and CSN tumor in 2020, with Mainland China, India, and Japan contributing to majority of the cases.

下載
2022/7/28 報告

Psoriasis - Asia Pacific –Clinical Trial Landscape

Of the approximately 30 million adult Psoriasis cases that were prevalent globally in 2017, the highest prevalences were found in the Asian region particularly India, Mainland China, and Japan.

下載
2022/7/27 報告

Solid tumors - Asia Pacific – Clinical trial Landscape

There were over 8.2 million new cases and over 5 million deaths due to solid cancers in Asia, with the region accounting for half of the new cancer cases and 60% of the world’s deaths in 2020.

下載
2022/7/13 報告

Multiple myeloma - Asia pacific – clinical Trial landscape

Multiple myeloma cases are increasing in Asia, with the region currently contributing to more than 35% of the projected global incidence, with China, India, and Japan comprising more than a quarter

下載
2022/7/13 報告

Covid-19 - asia pacific – Clinical trial landscape

Asia Pacific accounts for around 20% of the total COVID-19 cases reported globally with Taiwan, Australia, Japan, and South Korea reporting the highest number of new cases of COVID-19 in the region

下載
2022/6/22 報告

Parkinson’s disease - Asia pacific – clinical Trial landscape

Due to the presence of half of the world’s aging population and a high population growth rate in APAC, the global burden of Parkinson's Disease is expected to rise, with China, Japan, and India col

下載
2022/6/15 報告

Acute pancreatitis – Asia pacific – clinical Trial landscape

Owing to its huge, aged population base, Asia accounts for over 55% of the estimated global incidence of Acute pancreatitis, with China, Japan, and India collectively contributing to over a quarter

下載
2022/6/15 報告

Chronic pain - Asia pacific – clinical Trial landscape

In Asia Pacific, Chronic Pain affects more than half of the population, with China and India together contributing close to 700 million cases.

下載
2022/5/26 報告

Follicular lymphoma - Asia pacific - clinical Trial landscape

Owing to its large population base, Asia may account for over 40% of the estimated global incidence of Follicular Lymphoma, with China, Japan and India collectively contributing to over a quarter o

下載
2022/5/26 報告

Atopic dermatitis

Asia has been witnessing increasing levels of Atopic Dermatitis (AD) over the previous few decades, with the Paediatric AD prevalence rates in various Asian ethnicities reaching as high as 20%.

下載
2022/5/24 報告

Renal Cell Carcinoma

Owing to its large population base, Asia accounts for over 35% of the estimated global incidence of Renal cell carcinoma, with China, Japan, and India collectively contributing to over a quarter of

下載
2022/3/31 報告

Triple negative breast Cancer

With a high population density and over 45% of the global breast cancer incidence, Asia is expected to account for more than half of all TNBC cases, with a large TNBC patient pool, particularly in

下載
2022/3/17 報告

Disease report - CKD - APAC - CT Landscape

Diabetes and hypertension are expected to drive the global prevalence of CKD, with much of this increasing burden observed in Asian locations of China and India.

下載
2022/3/14 報告

Hepatitis B - Asia Pacific - Clinical trials Landscape

The Asia-Pacific with an intermediate to high prevalence, represents three-quarters of chronic hepatitis B (CHB)-positive subjects worldwide.

下載
2022/2/24 報告

Small cell lung cancer

Each year, there are over 300,000 new cases of Small Cell Lung Cancer globally, with Asia accounting for nearly 60% of the cases.

下載
2022/1/21 報告

Bladder cancer

Asia accounted for over a third of the global bladder cancer incidence with over 200,00 newly diagnosed cases, with China having a higher prevalence of bladder cancer in 2020.

下載
2022/1/21 報告

Thyroid cancer

Asia accounted for almost 60% of the global incidence, mortality and five-year prevalence in 2020, with the highest incidence rates found in Australia and Eastern Asia for both sexes.

下載
2021/12/17 報告

Cervical cancer Asia pacific Clinical trial landscape

Asia accounts for almost 60% of the global incidence of cervical cancer, with India and China together contributing to more than a third of all cases and deaths.

下載
2021/12/17 報告

Pancreatic cancer Clinical trials landscape Asia pacific

The incidence of pancreatic cancer is rising in Asia-Pacific, with the region accounting for about half of new cases in 2020.

下載
2021/12/17 報告

Gastric cancer Clinical trial landscape Asia-pacific

Nearly 75% of the new gastric cancer cases in the world are concentrated in Asia, with China showing the highest incidence and mortality.

下載
2021/11/29 報告

Colorectal cancer clinical trials landscape asia pacific

The incidence of colorectal cancer cases is rapidly growing in Asia-Pacific and the region now accounts for more than half of all new cases diagnosed globally.

下載
2021/11/29 報告

Lung cancer (nsclc) clinical trials landscape asia pacific

In Asia, lung cancer ranks as the most prevalent cancer and the primary cause of mortality, with the region accounting for almost 60% of the global incidence of lung cancer.

下載
2021/11/3 報告

Esophageal cancer – Clinical trials landscape – Asia pacific

In Asia, EC is the sixth most common cancer, with the region constituting almost 80% of the new EC cases globally. The highest standardized incidence rate has been observed in East Asia.

下載
2021/10/14 報告

Clinical trial landscape Of cll in asia-pacific

CLL is one of the most common forms of leukaemia, with the Asia Pacific region showing increasing incidence. China and South Korea are among the Asian locations showing the greatest incidence.

下載
2021/10/12 報告

Clinical trial landscape of Liver cancer in asia pacific

According to the Globocan 2020 report, liver cancer is the fourth most frequent cancer in Asia, with the region accounting for over 70% of all new liver cancer cases worldwide.

下載
2021/9/17 報告

Clinical trial landscape of diabetes (type 2) in asia-pacific

Diabetes, which is endemic in most Western countries, is now seeing a surge in developing nations across Asia due to aging, urbanization, and changing dietary habits.

下載
2021/9/17 報告

Clinical trial landscape of endometrial cancer in asia-pacific

In 2020, Globocan reported over 400,000 new corpus uteri cases, with Asia accounting for about 40% of these new cases.

下載
2021/8/27 報告

Clinical trial landscape of B-cell lymphoma in asia-pacific

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and the most aggressive subtype constituting nearly 70% of B-Cell Lymphomas in Asia.

下載
2021/8/20 報告

Clinical trial landscape of t-cell lymphomas in asia-pacific

T-cell lymphomas (TCLs) are types of non-Hodgkin’s lymphoma (NHL) that affect T lymphocytes.

下載
2021/8/18 報告

Cystic fibrosis-Clinical Trials Landscape-APAC

Cystic fibrosis is a rare autosomal recessive disease which primarily affects the lungs and digestive system due to a malfunction in the exocrine system responsible for producing saliva, sweat, tea

下載
2021/2/15 報告

AML Landscape in Asia-Pacific

AML is the most common form of leukemia in adults, accounting for approximately a third of all leukemia cases worldwide.

下載
2020/2/28 報告

澳洲臨床試驗的法規要求

憑藉簡化的法規環境，包括對 IND 無任何規定，以及在臨床研究支出上，有支持研發的政府退還金高達 43.5% ，讓澳洲成為早期臨床試驗的首選目的地。 過去幾年來，澳洲的臨床試驗案件數穩定成長，在 2016 年至 2018 年期間每年成長超過 10%。

下載
2020/2/5 報告

Accelerating Genetic Therapy Clinical Trials in Asia-Pacific

A growing number of biotechnology companies, both in the West and in Asia, are specializing in gene therapies and other regenerative treatments boosted by the approval of the first genetic therapy

下載
2020/2/4 報告

Accelerating Immunotherapy Clinical Trials in Asia-Pacific

Over 600 sites across Asia-Pacific have been involved in the clinical development of now approved IO drugs, and hundreds more are experienced in managing clinical trials with immunotherapies for bo

下載
2019/12/1 報告

加速亞太區的孤兒藥物試驗

近年來，我們觀察到前所未有的努力可見於孤兒藥的臨床開發上。事實上，在 2018 年，美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 批准的大多數的新藥都是孤兒藥。 本報告的目的，是要描述孤兒藥的發展現況，並解釋在全球局勢中，亞洲地區的地位是如何演進的。

下載